GSK highlights prevention

Saturday 4 November 2023

United Kingdom

GSK Plc highlighted disease prevention as a strategic objective for the company with the release of its third quarter results on 1 November. These showed a strong performance for the company’s vaccines for herpes zoster (shingles) and respiratory syncytial virus (RSV) which together generated £1.53 billion in the quarter, or 19% of total group turnover of £8.15 billion. Arexvy, an RSV vaccine for older adults, was approved in the US in May and in the EU in June.